140 related articles for article (PubMed ID: 25963963)
1. Infection: Ceftolozane-tazobactam gives a new ASPECT to the fight against antimicrobial resistance.
Edwards JK
Nat Rev Urol; 2015 Jun; 12(6):306. PubMed ID: 25963963
[No Abstract] [Full Text] [Related]
2. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Popa C; Mircheva M; Krämer BK; Berghofen A; Krüger B
Lancet; 2015 Sep; 386(10000):1241-1242. PubMed ID: 26460657
[No Abstract] [Full Text] [Related]
3. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Kielstein JT; Schmidt JJ
Lancet; 2015 Sep; 386(10000):1241. PubMed ID: 26460656
[No Abstract] [Full Text] [Related]
4. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Boyles T
Lancet; 2015 Sep; 386(10000):1241. PubMed ID: 26460655
[No Abstract] [Full Text] [Related]
5. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection - Authors' reply.
Wagenlehner FM; Umeh O; Darouiche RO
Lancet; 2015 Sep; 386(10000):1242. PubMed ID: 26460659
[No Abstract] [Full Text] [Related]
6. A new ASPECT for complicated urinary tract infections.
Chan JF; Yuen KY
Lancet; 2015 May; 385(9981):1920-2. PubMed ID: 25931245
[No Abstract] [Full Text] [Related]
7. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
Wagenlehner FM; Alidjanov JF
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
[TBL] [Abstract][Full Text] [Related]
11. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
12. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
15. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
17. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
19. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
Žemličková H; Jakubů V; Fridrichová M
Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Bassetti M; Righi E
Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]